Open Access Case report

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib

Elisa Castellani1, Piero Covarelli1, Carlo Boselli1, Roberto Cirocchi2, Antonio Rulli1, Francesco Barberini1, Daniela Caracappa1, Carla Cini1, Jacopo Desiderio2*, Gloria Burini1 and Giuseppe Noya1

Author Affiliations

1 Department of General and Oncologic Surgery, University of Perugia, Perugia, Italy

2 Department of General Surgery, University of Perugia, St. Maria Hospital, Via Tristano di Joannuccio, Terni, 05100, Italy

For all author emails, please log on.

World Journal of Surgical Oncology 2012, 10:155 doi:10.1186/1477-7819-10-155

Published: 30 July 2012

Abstract

Background

BRAF inhibitors such as vemurafenib are a new family of biological drugs, recently available to treat metastatic malignant melanoma.

Methods

We present the case of a 38-year-old man affected by metastatic melanoma who had been under treatment with vemurafenib for a few days. The patient suffered from sudden onset of abdominal pain due to intra-abdominal hemorrhage with profuse hemoperitoneum. An emergency abdominal sonography confirmed the clinical suspicion of a splenic rupture.

Results

The intraoperative finding was hemoperitoneum due to splenic two-step rupture and splenectomy was therefore performed. Histopathology confirmed splenic hematoma and capsule laceration, in the absence of metastasis.

Conclusions

This report describes the occurrence of a previously unreported adverse event in a patient with stage IV melanoma receiving vemurafenib.

Keywords:
Spontaneous splenic rupture; Melanoma; BRAF; Vemurafenib